MC Sciences builds upon a history of 25 years of scientific research and clinical experience with mast cell patients. Based upon a clinical observation of off-target effects in the 1980s by Prof. Gerhard Molderings, the co-founder of MC Sciences, followed by intensive investigation of mast cell biology, series of in-vitro experiments, and in-vivo tests have resulted in the discovery of a novel biology mast cell therapy platform.
Establishment of an human ex-vivo model with human tissues that confirms the inhibition mast cell activity of our lead moledule MCS10XX series.
Validation and confirmation of in-vitro mechanism of action and clear identification of pharmacophore as baseline for a new class of substances with known chemical properties.
The clinical discovery has been confirmed with good results in unpublished off-label clinical tests in around 300 patients with mast cell-related diseases confirming that the potential pharmacophore acts on a novel mast cell target and is highly efficacious.
30 years of intensive research of mast cell biology accompanied with investigating pharmacological treatment options for the world’s largest pool of mast cell disease patients – leading to the step-by-step investigation of the possible mechanism of action of the observed clinical observation.
Discovery by clinical observation of off-target effects that certain pharmacological properties have the capability to selectively inhibit activated mast cells through an unknown mechanism of action.